{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:07:10Z","timestamp":1789913230759,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jaut.2013.12.010","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T06:15:31Z","timestamp":1389161731000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Outcome measures for primary Sj\u00f6gren's syndrome: A comprehensive review"],"prefix":"10.1016","volume":"51","author":[{"given":"Rapha\u00e8le","family":"Seror","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2013.12.010_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaut.2013.12.010_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib5","first-page":"896","article-title":"A\u00a0double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.010_bib6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib8","first-page":"143","article-title":"Outcome measures for Sjogren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA","volume":"32","author":"Pillemer","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.010_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/rheumatology\/40.10.1180","article-title":"Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK","volume":"40","author":"Bowman","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/rheumatology\/40.10.1085","article-title":"Outcome measures in Sjogren's syndrome","volume":"40","author":"Asmussen","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib11","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","article-title":"Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma","volume":"64","author":"Pijpe","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib16","first-page":"S430","article-title":"Rituximab Treatment in primary Sj\u00f6gren's syndrome: a double-blind controlled trial","volume":"58","author":"Meijer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effective rituximab treatment in primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib18","first-page":"6","article-title":"Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome","volume":"29","author":"Devauchelle-Pensec","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.010_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/rheumatology\/keh170","article-title":"Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool","volume":"43","author":"Bowman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib20","first-page":"1259","article-title":"Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren's syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.010_bib21","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/art.22658","article-title":"Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients","volume":"56","author":"Vitali","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib22","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/kem280","article-title":"Sjogren's Systemic Clinical Activity Index (SCAI)\u2013a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome","volume":"46","author":"Bowman","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2012.01.013","article-title":"Outcome measures for primary Sjogren's syndrome","volume":"39","author":"Seror","year":"2012","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2013.12.010_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European League against rheumatism Sjogren's syndrome disease activity index and European league against rheumatism Sjogren's syndrome patient-reported index: a complete picture of primary Sjogren's syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaut.2013.12.010_bib27","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.jaut.2013.12.010_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/acr.20173","article-title":"Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European league against rheumatism Sjogren's syndrome disease activity index","volume":"62","author":"Seror","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaut.2013.12.010_bib29","first-page":"S1078","article-title":"Validation of EULAR primary Sj\u00f6gren's syndrome disease activity and patient indexes","volume":"64","author":"Seror","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib31","article-title":"EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial","author":"Moerman","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/annrheumdis-2013-eular.317","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (phase II open label ASAP study)","volume":"72( suppl)","author":"Meiners","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib33","first-page":"S926","article-title":"Results of the BELISS study, the first open phase 2 study of belimumab in primary Sjogren's syndrome","volume":"64","author":"Mariette","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib34","first-page":"510","article-title":"Relationship between disease activity of primary Sjogren's syndrome and Patient reported outcome \u2013 data from an interim analysis of the UK primary Sj\u00f6gren's syndrome registry","volume":"70","author":"Ng","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib35","first-page":"505","article-title":"Assessment of systemic disease activity is complementary to assessment of patient's symptoms in primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib36","first-page":"569","article-title":"Patients' complaints depend on systemic status in patient with primary Sj\u00f6gren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib38","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/art.38129","article-title":"The FMS-like tyrosine kinase 3-ligand may be biological marker of lymphoma in primary Sjogren's syndrome","author":"Tobon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib41","doi-asserted-by":"crossref","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2013.12.010_bib42","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1136\/ard.2011.153098","article-title":"Serum beta2 microglobulin correlates with the new ESSDAI in patients with Sjogren's syndrome","volume":"70","author":"Pertovaara","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib44","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/ar4245","article-title":"Peripheral regulatory cells immunophenotyping in Primary Sjogren's Syndrome: a cross-sectional study","volume":"15","author":"Furuzawa-Carballeda","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaut.2013.12.010_bib45","first-page":"293","article-title":"Expansion of CD4+CD25-GITR+ regulatory T-cell subset in the peripheral blood of patients with primary Sjogren's syndrome: correlation with disease activity","volume":"64","author":"Alunno","year":"2012","journal-title":"Rheumatism"},{"key":"10.1016\/j.jaut.2013.12.010_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket270","article-title":"The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients","author":"Cho","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.010_bib47","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/acr.21738","article-title":"Impaired functional status in primary Sjogren's syndrome","volume":"64","author":"Hackett","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaut.2013.12.010_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2012-eular.3189","article-title":"How good are the EULAR sj\u00f6gren's syndrome disease activity index (ESSDAI), and eular sj\u00f6gren's syndrome patients reported index (ESSPRI) in predicting health status in primary sj\u00f6gren's syndrome?","volume":"71","author":"Ng","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jaut.2013.12.010_bib49","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2013.12.010_bib50","article-title":"Inefficacy of hydroxychoroquine in primary Sj\u00f6gren's syndrome: results of the JOQUER trial","volume":"64","author":"Gottenberg","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib51","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2012-eular.1748","article-title":"Tolerance and efficacy of rituximab in primary Sj\u00f6gren's syndrome (TEARS): results of a randomized controlled trial","volume":"71","author":"Devauchelle-Pensec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib53","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the autoimmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib54","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.010_bib55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib56","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.010_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2013.12.010_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.57.1.20","article-title":"Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study","volume":"57","author":"Hay","year":"1998","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:09:26Z","timestamp":1760256566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841113001571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":58,"alternative-id":["S0896841113001571"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.010","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome measures for primary Sj\u00f6gren's syndrome: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}